The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Background Platinum-based chemotherapy is the recommended adjuvant treatment for
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …

Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …

Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …

Conventional chemotherapeutics have been developed into clinically useful agents based
on their ability to preferentially kill malignant cells, generally owing to their elevated …

Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Importance Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as
monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 …

Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …

Abstract Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely
used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI …